<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02418819</url>
  </required_header>
  <id_info>
    <org_study_id>B7441007</org_study_id>
    <nct_id>NCT02418819</nct_id>
  </id_info>
  <brief_title>A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, SPONSOR OPEN, PHASE 1B STUDY TO EXAMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-06412562 IN PSYCHIATRICALLY STABLE SUBJECTS WITH SCHIZOPHRENIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the safety, tolerability pharmacokinetics and
      pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets
      in subjects with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      B7441007 is a randomized, double-blind, placebo-controlled, sponsor open, parallel group
      design, Phase 1b study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      3 doses of PF-06412562 (3 mg BID, 9 mg BID and 45 mg BID) over 15 days in approximately 100
      psychiatrically stable (as defined by the inclusion and exclusion criteria) subjects with
      schizophrenia are on background treatment with SOC antipsychotics and other psychotropic
      medications.

      All doses will be administered twice daily, with approximately 12 hours between each dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to 7-10 days after last dose of study drug, up to 26 days</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any events occurring following start of treatment or increasing in severity were counted as treatment emergent. AEs included both serious and non-serious AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Supine and Standing Vital Signs Meeting Categorical Summarization Criteria</measure>
    <time_frame>Baseline up to 7-10 days after last dose of study drug, up to 26 days</time_frame>
    <description>Vital Signs tests included systolic and diastolic blood pressure (BP) and pulse rate of seated supine and standing . Vital signs categorical summarization criteria were 1), supine and standing BP: systolic (SBP) greater than or equal to (&gt;=) 30 millimeters of mercury (mm Hg) change from baseline, systolic less than (&lt;) 90 mm Hg; diastolic BP (DBP) &gt;=20 mm Hg change from baseline, diastolic &lt;50 mm Hg; 2), supine and standing pulse rate &lt;40 or greater than (&gt;) 120 beats per minute (bpm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Electrocardiogram (ECG) (Standard 12‑Lead) Data Meeting Categorical Summarization Criteria</measure>
    <time_frame>Baseline up to 7-10 days after last dose of study drug, up to 26 days</time_frame>
    <description>ECG categorical summarization criteria were 1), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval): more than or equal to (&gt;=) 200 milliseconds (msec); for percent change(PChg), &gt;=25 percent (%) increase when baseline (b)&gt;100 msec; or increase &gt;=50% when b less than or equal to (&lt;=)100 msec; 2), the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval): &gt;=300 msec; &gt;=25percent (%) increase when b &gt;200 msec; or increase &gt;=50% when b &lt;=200 msec; 3), time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula (QTcF interval): absolute value &gt;=450 - &lt;480 msec, &gt;=480-&lt;500 msec and &gt;=500 msec; increase from b &gt;=30 - &lt;60 and &gt;=60 msec</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Blood and Urine Safety Laboratory Test Abnormalities</measure>
    <time_frame>Baseline up to Day 15</time_frame>
    <description>The total number of participants with blood and urine laboratory test abnormalities (without regard to baseline abnormality) was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis, and some other tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With New Onset and Worsening of Post Baseline Suicidality in Columbia Suicide Severity Rating Scale (C‑SSRS) on Day 1, Day 7 and Follow-up.</measure>
    <time_frame>Baseline, Days 1,7 and follow-up (7-10 days after last dose of study drug, up to 26 days)</time_frame>
    <description>The C-SSRS was an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. Versions were available for Screening/Baseline and follow-up visits. Post-baseline suicidality was displayed without regard to baseline and as new onset or worsening relative to baseline. A participant was considered to have a new onset of suicidality if the participant reported no ideation and no behavior at the baseline assessment. A participant was considered to have a worsening of suicidality if the participant moved to a lower numbered Columbia Classification Algorithm of Suicide Assessment (C-CASA) category (observed in categories 1-4) than was reported at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Day 13 of Wechsler Memory Scale (WMS III) Spatial Span + Letter Number Span Composite Score (Working Memory Domain)</measure>
    <time_frame>Baseline, Day 13</time_frame>
    <description>MCCB measures cognitive function across cognitive domains and is comprised of 10 independent tests assessing 7 cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition). A subset of the MCCB cognitive domain was used to assess working memory of participants. Total score range of this subset ranges from 40 (minimum score) to 60 (maximum score), with higher scores indicating better cognitive function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Blood Oxygen Level Dependent (BOLD) fMRI Activation Parameter Estimates (Z-scores) in Anterior Ventral Striatum Region of Interest (ROI) for the Contrast of Cue Gain &gt; Cue No Gain in Monetary Incentive Delay (MID) Task on Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>MRI parameter estimates refer to the 90th percentile Z-statistics across all voxels within the Region of Interest (ROI). This task provided a measure of reward anticipation and reward consummation. One of 3 shapes was presented on the screen (each uniquely associated with gain, loss and neutral) as a cue, and participants were instructed to respond to each cue, using their dominant hand, by pressing in response to a subsequent target that appeared for a variable length of time. Baseline was defined as Day 0 assessment. To be included in analysis participants must have complete Monetary Incentive Delay (MID) data at both Baseline and post-baseline, without excessive head motion. Participants with MID &lt;40% at baseline were excluded from the analysis and summary statistics. Scores were not bounded by a minimum or maximum range, higher z-score implies a greater motivation of the participant by the prospect of monetary gain than no monetary gain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of PF-06412562 for Each Dose.</measure>
    <time_frame>6, and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day 16</time_frame>
    <description>PF-06412562 plasma concentration for each dose at 6 and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of PF-06663872 at for Each Dose.</measure>
    <time_frame>6 and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day16</time_frame>
    <description>PF-06412562 plasma concentration for each dose at times 6 and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day 16.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>PF-06412562 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06412562 3mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06412562 9mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06412562 9mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06412562 45mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06412562 45mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06412562 3mg BID</intervention_name>
    <description>PF-06412562</description>
    <arm_group_label>PF-06412562 3mg</arm_group_label>
    <other_name>PF-06412562 3mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06412562 9mg BID</intervention_name>
    <description>PF-06412562</description>
    <arm_group_label>PF-06412562 9mg</arm_group_label>
    <other_name>PF-06412562 9mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06412562 45mg BID</intervention_name>
    <description>PF-06412562</description>
    <arm_group_label>PF-06412562 45mg</arm_group_label>
    <other_name>PF-06412562 45mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with schizophrenia both male and female

          2. Evidence of stable schizophrenia symptomatology for at least 3 months (no
             hospitalizations for schizophrenia, no increase in level of psychiatric care due to
             worsening of symptoms of schizophrenia, etc).

          3. Subjects must be in ongoing maintenance antipsychotic therapy other than clozapine
             (oral or depot) on a stable medication treatment regimen for for at least 2 months
             prior to Day 1, including concomitant psychotropic medications.

        Exclusion Criteria:

          1. History of seizure

          2. Pregnant or nursing females

          3. Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease
             (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies
             at time of screening and at the time of dosing).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arcadia MRI &amp; Imaging Center</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center (MPRC) of the University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CBH Health, LLC</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foers Long Term Care Pharmacy LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7441007&amp;StudyName=A%20Randomized%2C%20Double-blind%2C%20Placebo%20Controlled%2C%20Parallel%20Group%2C%20Sponsor%20Open%2C%20Phase%201b%20Study%20To%20Examine%20The%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%2C%20And%20Pharmacodynamics%20Of%20Pf%2006412562%20In%20Psychiatrically%20Stable%20Subjects%20With%20Schizophrenia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <results_first_submitted>August 3, 2017</results_first_submitted>
  <results_first_submitted_qc>February 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 4, 2019</results_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 103 participants were randomized and assigned to study treatment. One (1) participant in the PF-06412562 3 mg twice a day (BID) group and 2 participants in the PF-06412562 45 mg BID group did not receive study drug. Therefore, 100 participants received study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PF-06412562 3 mg BID</title>
          <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
        </group>
        <group group_id="P2">
          <title>PF-06412562 9 mg BID</title>
          <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
        </group>
        <group group_id="P3">
          <title>PF-06412562 45 mg BID</title>
          <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Participant received placebo matched to PF 06412562 3 mg and 15 mg modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PF-06412562 3 mg BID</title>
          <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
        </group>
        <group group_id="B2">
          <title>PF-06412562 9 mg BID</title>
          <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
        </group>
        <group group_id="B3">
          <title>PF-06412562 45 mg BID</title>
          <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Participant received placebo matched to PF 06412562 3 mg and 15 mg modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="29"/>
            <count group_id="B5" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="6.1"/>
                    <measurement group_id="B2" value="34.3" spread="7.2"/>
                    <measurement group_id="B3" value="33.8" spread="6.9"/>
                    <measurement group_id="B4" value="35.7" spread="5.8"/>
                    <measurement group_id="B5" value="34.9" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any events occurring following start of treatment or increasing in severity were counted as treatment emergent. AEs included both serious and non-serious AEs.</description>
        <time_frame>Baseline up to 7-10 days after last dose of study drug, up to 26 days</time_frame>
        <population>The safety analysis set was used, defined as all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06412562 3 mg BID</title>
            <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06412562 9 mg BID</title>
            <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06412562 45 mg BID</title>
            <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participant received placebo matched to PF 06412562 3 mg and 15 mg modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any events occurring following start of treatment or increasing in severity were counted as treatment emergent. AEs included both serious and non-serious AEs.</description>
          <population>The safety analysis set was used, defined as all participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Supine and Standing Vital Signs Meeting Categorical Summarization Criteria</title>
        <description>Vital Signs tests included systolic and diastolic blood pressure (BP) and pulse rate of seated supine and standing . Vital signs categorical summarization criteria were 1), supine and standing BP: systolic (SBP) greater than or equal to (&gt;=) 30 millimeters of mercury (mm Hg) change from baseline, systolic less than (&lt;) 90 mm Hg; diastolic BP (DBP) &gt;=20 mm Hg change from baseline, diastolic &lt;50 mm Hg; 2), supine and standing pulse rate &lt;40 or greater than (&gt;) 120 beats per minute (bpm).</description>
        <time_frame>Baseline up to 7-10 days after last dose of study drug, up to 26 days</time_frame>
        <population>The safety analysis set was used, which defined as all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06412562 3 mg BID</title>
            <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06412562 9 mg BID</title>
            <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06412562 45 mg BID</title>
            <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participant received placebo matched to PF 06412562 3 mg and 15 mg modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Supine and Standing Vital Signs Meeting Categorical Summarization Criteria</title>
          <description>Vital Signs tests included systolic and diastolic blood pressure (BP) and pulse rate of seated supine and standing . Vital signs categorical summarization criteria were 1), supine and standing BP: systolic (SBP) greater than or equal to (&gt;=) 30 millimeters of mercury (mm Hg) change from baseline, systolic less than (&lt;) 90 mm Hg; diastolic BP (DBP) &gt;=20 mm Hg change from baseline, diastolic &lt;50 mm Hg; 2), supine and standing pulse rate &lt;40 or greater than (&gt;) 120 beats per minute (bpm).</description>
          <population>The safety analysis set was used, which defined as all participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine SBP &lt;90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing SBP &lt;90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing DBP &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine Pulse rate &lt;40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine Pulse rate &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing Pulse rate &lt;40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standing Pulse rate &gt;140 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase: supine SBP &gt;=30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase: standing SBP &gt;=30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase: supine DBP &gt;=20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase: standing DBP &gt;=20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: supine SBP &gt;= 30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: standing SBP &gt;= 30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: supine DBP &gt;=20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease: standing DBP &gt;=20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Electrocardiogram (ECG) (Standard 12‑Lead) Data Meeting Categorical Summarization Criteria</title>
        <description>ECG categorical summarization criteria were 1), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval): more than or equal to (&gt;=) 200 milliseconds (msec); for percent change(PChg), &gt;=25 percent (%) increase when baseline (b)&gt;100 msec; or increase &gt;=50% when b less than or equal to (&lt;=)100 msec; 2), the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval): &gt;=300 msec; &gt;=25percent (%) increase when b &gt;200 msec; or increase &gt;=50% when b &lt;=200 msec; 3), time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula (QTcF interval): absolute value &gt;=450 - &lt;480 msec, &gt;=480-&lt;500 msec and &gt;=500 msec; increase from b &gt;=30 - &lt;60 and &gt;=60 msec</description>
        <time_frame>Baseline up to 7-10 days after last dose of study drug, up to 26 days</time_frame>
        <population>The safety analysis set was used, defined as all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06412562 3 mg BID</title>
            <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06412562 9 mg BID</title>
            <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06412562 45 mg BID</title>
            <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participant received placebo matched to PF 06412562 3 mg and 15 mg modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram (ECG) (Standard 12‑Lead) Data Meeting Categorical Summarization Criteria</title>
          <description>ECG categorical summarization criteria were 1), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval): more than or equal to (&gt;=) 200 milliseconds (msec); for percent change(PChg), &gt;=25 percent (%) increase when baseline (b)&gt;100 msec; or increase &gt;=50% when b less than or equal to (&lt;=)100 msec; 2), the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval): &gt;=300 msec; &gt;=25percent (%) increase when b &gt;200 msec; or increase &gt;=50% when b &lt;=200 msec; 3), time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula (QTcF interval): absolute value &gt;=450 - &lt;480 msec, &gt;=480-&lt;500 msec and &gt;=500 msec; increase from b &gt;=30 - &lt;60 and &gt;=60 msec</description>
          <population>The safety analysis set was used, defined as all participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval &gt;=300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS complex &gt;=200 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval 450-480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval 480-500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval &gt;=500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval increase b&gt;200 &amp; PChg&gt;=25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval increase b&lt;=200 &amp; PChg&gt;=50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS complex increase b&gt;100 &amp; PChg&gt;=25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS complex increase b&lt;=100 &amp; PChg&gt;=50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval increase 30-60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval increase &gt;=60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Blood and Urine Safety Laboratory Test Abnormalities</title>
        <description>The total number of participants with blood and urine laboratory test abnormalities (without regard to baseline abnormality) was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis, and some other tests.</description>
        <time_frame>Baseline up to Day 15</time_frame>
        <population>The safety analysis set was used, defined as all participants who received at least 1 dose of study medication. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06412562 3 mg BID</title>
            <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06412562 9 mg BID</title>
            <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06412562 45 mg BID</title>
            <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participant received placebo matched to PF 06412562 3 mg and 15 mg modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Blood and Urine Safety Laboratory Test Abnormalities</title>
          <description>The total number of participants with blood and urine laboratory test abnormalities (without regard to baseline abnormality) was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis, and some other tests.</description>
          <population>The safety analysis set was used, defined as all participants who received at least 1 dose of study medication. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With New Onset and Worsening of Post Baseline Suicidality in Columbia Suicide Severity Rating Scale (C‑SSRS) on Day 1, Day 7 and Follow-up.</title>
        <description>The C-SSRS was an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. Versions were available for Screening/Baseline and follow-up visits. Post-baseline suicidality was displayed without regard to baseline and as new onset or worsening relative to baseline. A participant was considered to have a new onset of suicidality if the participant reported no ideation and no behavior at the baseline assessment. A participant was considered to have a worsening of suicidality if the participant moved to a lower numbered Columbia Classification Algorithm of Suicide Assessment (C-CASA) category (observed in categories 1-4) than was reported at baseline.</description>
        <time_frame>Baseline, Days 1,7 and follow-up (7-10 days after last dose of study drug, up to 26 days)</time_frame>
        <population>The safety analysis set was used, defined as all participants who received at least 1 dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06412562 3 mg BID</title>
            <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06412562 9 mg BID</title>
            <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06412562 45 mg BID</title>
            <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participant received placebo matched to PF 06412562 3 mg and 15 mg modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Onset and Worsening of Post Baseline Suicidality in Columbia Suicide Severity Rating Scale (C‑SSRS) on Day 1, Day 7 and Follow-up.</title>
          <description>The C-SSRS was an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. Versions were available for Screening/Baseline and follow-up visits. Post-baseline suicidality was displayed without regard to baseline and as new onset or worsening relative to baseline. A participant was considered to have a new onset of suicidality if the participant reported no ideation and no behavior at the baseline assessment. A participant was considered to have a worsening of suicidality if the participant moved to a lower numbered Columbia Classification Algorithm of Suicide Assessment (C-CASA) category (observed in categories 1-4) than was reported at baseline.</description>
          <population>The safety analysis set was used, defined as all participants who received at least 1 dose of study medication</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day1 New Onset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day7 New Onset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day7 Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up New Onset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Day 13 of Wechsler Memory Scale (WMS III) Spatial Span + Letter Number Span Composite Score (Working Memory Domain)</title>
        <description>MCCB measures cognitive function across cognitive domains and is comprised of 10 independent tests assessing 7 cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition). A subset of the MCCB cognitive domain was used to assess working memory of participants. Total score range of this subset ranges from 40 (minimum score) to 60 (maximum score), with higher scores indicating better cognitive function.</description>
        <time_frame>Baseline, Day 13</time_frame>
        <population>Per Protocol Analysis Set (PPAS)subset of Full Analysis Set(FAS).Criteria:1)Received all doses of study treatment to which they randomized2)No major protocol deviation3)Had baseline measurement and at least 1 post baseline measurement for at least 1 PD endpoint.Overall Number of Participants Analyzed=participants evaluable in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06412562 3 mg BID</title>
            <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06412562 9 mg BID</title>
            <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06412562 45 mg BID</title>
            <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participant received placebo matched to PF 06412562 3 mg and 15 mg modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 13 of Wechsler Memory Scale (WMS III) Spatial Span + Letter Number Span Composite Score (Working Memory Domain)</title>
          <description>MCCB measures cognitive function across cognitive domains and is comprised of 10 independent tests assessing 7 cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition). A subset of the MCCB cognitive domain was used to assess working memory of participants. Total score range of this subset ranges from 40 (minimum score) to 60 (maximum score), with higher scores indicating better cognitive function.</description>
          <population>Per Protocol Analysis Set (PPAS)subset of Full Analysis Set(FAS).Criteria:1)Received all doses of study treatment to which they randomized2)No major protocol deviation3)Had baseline measurement and at least 1 post baseline measurement for at least 1 PD endpoint.Overall Number of Participants Analyzed=participants evaluable in this outcome measure.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" spread="8.20"/>
                    <measurement group_id="O2" value="3.13" spread="7.90"/>
                    <measurement group_id="O3" value="1.28" spread="7.51"/>
                    <measurement group_id="O4" value="5.25" spread="6.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline is defined as the Day -2 assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8243</p_value>
            <method>ANCOVA</method>
            <method_desc>One(1)-sided P-values were obtained from an ANCOVA model on change from baseline with baseline, treatment, site, gender and age as fixed effects.</method_desc>
            <param_type>LSMean difference from placebo</param_type>
            <param_value>-1.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.032</dispersion_value>
            <ci_percent>92</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-4.78</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline is defined as the Day -2 assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8277</p_value>
            <method>ANCOVA</method>
            <method_desc>One(1)-side P-values were obtained from an ANCOVA model on change from baseline with baseline, treatment, site, gender and age as fixed effects.</method_desc>
            <param_type>LSMean difference from placebo</param_type>
            <param_value>-2.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.252</dispersion_value>
            <ci_percent>92</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-5.33</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline is defined as the Day -2 assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9810</p_value>
            <method>ANCOVA</method>
            <method_desc>One(1)-side P-values were obtained from an ANCOVA model on change from baseline with baseline, treatment, site, gender and age as fixed effects.</method_desc>
            <param_type>LSMean difference from placebo</param_type>
            <param_value>-4.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.902</dispersion_value>
            <ci_percent>92</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-6.70</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Blood Oxygen Level Dependent (BOLD) fMRI Activation Parameter Estimates (Z-scores) in Anterior Ventral Striatum Region of Interest (ROI) for the Contrast of Cue Gain &gt; Cue No Gain in Monetary Incentive Delay (MID) Task on Day 15</title>
        <description>MRI parameter estimates refer to the 90th percentile Z-statistics across all voxels within the Region of Interest (ROI). This task provided a measure of reward anticipation and reward consummation. One of 3 shapes was presented on the screen (each uniquely associated with gain, loss and neutral) as a cue, and participants were instructed to respond to each cue, using their dominant hand, by pressing in response to a subsequent target that appeared for a variable length of time. Baseline was defined as Day 0 assessment. To be included in analysis participants must have complete Monetary Incentive Delay (MID) data at both Baseline and post-baseline, without excessive head motion. Participants with MID &lt;40% at baseline were excluded from the analysis and summary statistics. Scores were not bounded by a minimum or maximum range, higher z-score implies a greater motivation of the participant by the prospect of monetary gain than no monetary gain.</description>
        <time_frame>Baseline, Day 15</time_frame>
        <population>PPAS was used,defined as subset of FAS dataset.Criteria for PPAS:1)Received all doses of study treatment to which they were randomized;2)No major protocol deviation;3)Had a baseline measurement and at least 1 post baseline measurement for at least 1 PD endpoint.Overall Number of Participants Analyzed=participants evaluable in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06412562 3 mg BID</title>
            <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06412562 9 mg BID</title>
            <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06412562 45 mg BID</title>
            <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participant received placebo matched to PF 06412562 3 mg and 15 mg modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Oxygen Level Dependent (BOLD) fMRI Activation Parameter Estimates (Z-scores) in Anterior Ventral Striatum Region of Interest (ROI) for the Contrast of Cue Gain &gt; Cue No Gain in Monetary Incentive Delay (MID) Task on Day 15</title>
          <description>MRI parameter estimates refer to the 90th percentile Z-statistics across all voxels within the Region of Interest (ROI). This task provided a measure of reward anticipation and reward consummation. One of 3 shapes was presented on the screen (each uniquely associated with gain, loss and neutral) as a cue, and participants were instructed to respond to each cue, using their dominant hand, by pressing in response to a subsequent target that appeared for a variable length of time. Baseline was defined as Day 0 assessment. To be included in analysis participants must have complete Monetary Incentive Delay (MID) data at both Baseline and post-baseline, without excessive head motion. Participants with MID &lt;40% at baseline were excluded from the analysis and summary statistics. Scores were not bounded by a minimum or maximum range, higher z-score implies a greater motivation of the participant by the prospect of monetary gain than no monetary gain.</description>
          <population>PPAS was used,defined as subset of FAS dataset.Criteria for PPAS:1)Received all doses of study treatment to which they were randomized;2)No major protocol deviation;3)Had a baseline measurement and at least 1 post baseline measurement for at least 1 PD endpoint.Overall Number of Participants Analyzed=participants evaluable in this outcome measure.</population>
          <units>Z scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.045" spread="1.092"/>
                    <measurement group_id="O2" value="-0.229" spread="1.042"/>
                    <measurement group_id="O3" value="0.075" spread="1.139"/>
                    <measurement group_id="O4" value="-0.048" spread="0.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline is defined as the Day 0 assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4821</p_value>
            <method>ANCOVA</method>
            <method_desc>One (1)-side P-values were obtained from an ANCOVA model on change from baseline with baseline, treatment, site, gender and age as fixed effects.</method_desc>
            <param_type>LSMean difference from placebo</param_type>
            <param_value>0.0129</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2860</dispersion_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.6682</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline is defined as the Day 0 assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8576</p_value>
            <method>ANCOVA</method>
            <method_desc>One (1)-side P-values were obtained from an ANCOVA model on change from baseline with baseline, treatment, site, gender and age as fixed effects.</method_desc>
            <param_type>LSMean difference from placebo</param_type>
            <param_value>-0.2974</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2760</dispersion_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.9547</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline is defined as the Day 0 assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4182</p_value>
            <method>ANCOVA</method>
            <method_desc>One(1)-side P-values were obtained from an ANCOVA model on change from baseline with baseline, treatment, site, gender and age as fixed effects.</method_desc>
            <param_type>LSMean difference from placebo</param_type>
            <param_value>0.0498</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2403</dispersion_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.5226</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of PF-06412562 for Each Dose.</title>
        <description>PF-06412562 plasma concentration for each dose at 6 and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day 16.</description>
        <time_frame>6, and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day 16</time_frame>
        <population>The PK concentration analysis set was defined as all participants randomized and treated who had at least 1 PK concentration. Here, “number analyzed” signifies the participants evaluable for each time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06412562 3 mg BID</title>
            <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06412562 9 mg BID</title>
            <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06412562 45 mg BID</title>
            <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of PF-06412562 for Each Dose.</title>
          <description>PF-06412562 plasma concentration for each dose at 6 and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day 16.</description>
          <population>The PK concentration analysis set was defined as all participants randomized and treated who had at least 1 PK concentration. Here, “number analyzed” signifies the participants evaluable for each time points.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6h on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.99" spread="5.315"/>
                    <measurement group_id="O2" value="61.59" spread="26.366"/>
                    <measurement group_id="O3" value="100.9" spread="41.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12h on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.14" spread="5.8686"/>
                    <measurement group_id="O2" value="47.88" spread="18.211"/>
                    <measurement group_id="O3" value="79.67" spread="37.939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6h on Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.89" spread="34.585"/>
                    <measurement group_id="O2" value="113.8" spread="44.331"/>
                    <measurement group_id="O3" value="581.1" spread="309.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12h on Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.65" spread="24.259"/>
                    <measurement group_id="O2" value="72.59" spread="31.865"/>
                    <measurement group_id="O3" value="365.3" spread="179.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6h on Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.47" spread="10.815"/>
                    <measurement group_id="O2" value="92.39" spread="44.805"/>
                    <measurement group_id="O3" value="533.2" spread="298.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12h on Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.34" spread="12.383"/>
                    <measurement group_id="O2" value="67.34" spread="36.958"/>
                    <measurement group_id="O3" value="357.0" spread="160.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0h on Day 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.14" spread="24.418"/>
                    <measurement group_id="O2" value="24.96" spread="17.571"/>
                    <measurement group_id="O3" value="164.9" spread="105.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of PF-06663872 at for Each Dose.</title>
        <description>PF-06412562 plasma concentration for each dose at times 6 and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day 16.</description>
        <time_frame>6 and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day16</time_frame>
        <population>The PK concentration analysis set was defined as all participants randomized and treated who had at least 1 PK concentration. Here, “number analyzed” signifies the participants evaluable for each time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06412562 3 mg BID</title>
            <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06412562 9 mg BID</title>
            <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06412562 45 mg BID</title>
            <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of PF-06663872 at for Each Dose.</title>
          <description>PF-06412562 plasma concentration for each dose at times 6 and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day 16.</description>
          <population>The PK concentration analysis set was defined as all participants randomized and treated who had at least 1 PK concentration. Here, “number analyzed” signifies the participants evaluable for each time points.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6h on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.707" spread="0.45216"/>
                    <measurement group_id="O2" value="5.649" spread="3.1174"/>
                    <measurement group_id="O3" value="8.894" spread="4.1986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12h on Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.948" spread="0.44567"/>
                    <measurement group_id="O2" value="5.355" spread="2.0234"/>
                    <measurement group_id="O3" value="8.108" spread="3.4277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6h on Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.289" spread="4.6182"/>
                    <measurement group_id="O2" value="12.00" spread="3.3004"/>
                    <measurement group_id="O3" value="58.36" spread="22.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12h on Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.218" spread="4.9360"/>
                    <measurement group_id="O2" value="8.758" spread="3.3431"/>
                    <measurement group_id="O3" value="43.06" spread="16.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6h on Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.733" spread="1.1179"/>
                    <measurement group_id="O2" value="10.27" spread="4.9097"/>
                    <measurement group_id="O3" value="53.39" spread="24.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12h on Day 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.144" spread="0.95169"/>
                    <measurement group_id="O2" value="8.604" spread="4.2130"/>
                    <measurement group_id="O3" value="40.95" spread="14.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0h on Day 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.925" spread="4.8908"/>
                    <measurement group_id="O2" value="3.432" spread="2.1968"/>
                    <measurement group_id="O3" value="19.25" spread="9.0442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 7-10 days after last dose of study drug, up to 26 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PF-06412562 3 mg BID</title>
          <description>Participant received 3 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
        </group>
        <group group_id="E2">
          <title>PF-06412562 9 mg BID</title>
          <description>Participant received 9 mg PF 06412562 modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
        </group>
        <group group_id="E3">
          <title>PF-06412562 45 mg BID</title>
          <description>Participant received 45 mg PF 06412562 modified release tablets were orally administered twice daily using a titration scheme (15 mg BID for 2 days, 30 mg BID for 2 days and 45 mg BID for the rest of the study) for 15 days with approximately 12 hours between each dose.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Participant received placebo matched to PF 06412562 3 mg and 15 mg modified release tablets were orally administered twice daily for 15 days with approximately 12 hours between each dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

